Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06543667RecruitingPhase 1
Stem cell eye drops for dry eye treatment
This trial tests a new eye drop made from stem cells to see if it can help relieve dry eye symptoms. It is for people with moderate to severe dry eye who haven't had recent eye surgery or used other eye drops.
TehranAges 18–70 - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT06547528RecruitingPhase 1
Testing ONO-4685 for T cell lymphoma and CLL/SLL
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Nagoya, Aichi-kenAges 18 years+ - NCT06548867Recruiting
Study of cabozantinib in advanced kidney cancer patients
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
Reggio EmiliaAges 18 years+ - NCT06551155Recruiting
Blood test to screen bone health and fracture risk
This study uses a simple blood test to look for early signs of bone loss and fracture risk. It's for people 40 and older who are either healthy, have early bone thinning, or have known osteoporosis.
BolognaAges 40 years+ - NCT06553339RecruitingPhase 1
A study of HS-10516 for VHL syndrome tumors
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–80 - NCT06554600RecruitingPhase 2
Study of zanubrutinib plus polatuzumab, bendamustine, and rituximab for relapsed DLBCL
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hanzhou, ZhejiangAges 18–75 - NCT06555939Recruiting
Resilience program for teens and young adults with sickle cell disease
This study tests a program called PRISM that helps teens and young adults with sickle cell disease build resilience and manage stress, anxiety, or depression. You may be eligible if you have sickle cell disease and feel down or worried.
Boston, MassachusettsAges 8–25 - NCT06557343Recruiting
Lung Cell Study After Chest Radiation
This study looks at cells from the lungs of people who developed lung inflammation after chest radiation for cancer. It aims to understand why some people get this reaction, which may help find better treatments.
EdinburghAges 18 years+ - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06559189RecruitingPhase 1
A new CAR T therapy for children with relapsed B-ALL
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Aurora, ColoradoAges 3 months–30 years - NCT06561360RecruitingPhase 2
Comparing two treatments for hairy cell leukemia
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
Boston, MassachusettsAges 18 years+ - NCT06562920RecruitingPhase 2
Immunotherapy plus chemo and SBRT before surgery for limited-stage small cell lung cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06563869RecruitingPhase 3
Sintilimab with chemo and growth factor before esophageal cancer surgery
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Nanjing, JiangsuAges 18–75 - NCT06564233Recruiting
Support program for stem cell transplant patients
This trial tests a supportive care program using an avatar to help patients going through a stem cell transplant. It aims to improve your experience and outcomes during recovery.
Boston, MassachusettsAges 19 years+ - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT06565026RecruitingEarly Phase 1
CS-206 treatment for sickle cell disease patients
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
Nanning, GuangxiAges 12–35 - NCT06566443RecruitingPhase 1
Honokiol for early-stage lung cancer before surgery
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Houston, TexasAges 18 years+ - NCT06566586RecruitingPhase 2
Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06568328RecruitingPhase 1
Experimental cell therapy for severe graft-versus-host disease
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
Fuzhou, FujianAges 1–70 - NCT06570291RecruitingPhase 3
Stem cell injection for knee osteoarthritis
This trial tests a new treatment using donor stem cells injected into the knee for people with moderate knee osteoarthritis. It aims to see if these cells can reduce pain and improve function.
Shanghai, ChinaAges 40–75 - NCT06572618RecruitingPhase 2
Nemtabrutinib plus rituximab for first-line mantle cell lymphoma
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT06575322Recruiting
Neoadjuvant therapy for head and neck cancer: effects on pain and mood
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
Guanzhou, GuangdongAges 18–80 - NCT06576180Recruiting
Chemo-immunotherapy and cognition in head and neck cancer
This trial is studying whether a combination of chemotherapy (carboplatin and paclitaxel) and an immunotherapy drug (anti-PD-1) affects memory and thinking in people with head and neck cancer that can be removed with surgery. Researchers want to see if these treatments cause any cognitive changes.
Guanzhou, GuangdongAges 18–80
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.